Review Article: Prostate CancerVEGF and prostatic cancer: a systematic reviewBotelho, Franciscoa b; Pina, Franciscoa; Lunet, Nunob cAuthor Information aDepartment of Urology, Hospital de S. João bDepartment of Hygiene and Epidemiology, University of Porto Medical School cInstitute of Public Health, University of Porto, Porto, Portugal Correspondence to Dr Francisco Botelho, MD, Serviço de Higiene e Epidemiologia – Faculdade de Medicina da Universidade do Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal Tel: +351 913650130; fax: +351 225095618; e-mail: [email protected] Received 10 December 2009 Accepted 4 April 2010 European Journal of Cancer Prevention: September 2010 - Volume 19 - Issue 5 - p 385-392 doi: 10.1097/CEJ.0b013e32833b48e1 Buy Metrics Abstract Elevated vascular endothelial growth factor (VEGF) blood concentration reflects its prostatic production, making this a potentially interesting tumour marker to support the decision of submitting a patient for prostatic biopsy. The objective was to review systematically the evidence on the role of VEGF blood concentration in prostate cancer detection. Published studies addressing the relation between serum or plasma VEGF levels and prostate cancer were identified by searching Pubmed, ISI Web of Knowledge, SCOPUS and LILACS up to January 2010, and reviewed following a standardized protocol. Three studies reported higher plasma VEGF (pg/ml) in patients with localized prostate cancer than in healthy controls (7.0 vs. 0.0, 9.9 vs. 2.2, and 210 vs. 26.5, P<0.01), and two showed higher serum VEGF (pg/ml) in prostate cancer patients than in patients with benign prostate hypertrophy (518.9 vs. 267.9, P<0.001; no specific values, P<0.05). In one study, serum VEGF was significantly lower in healthy controls than in patients with benign prostate hypertrophy, localized or metastatic prostate cancer. The three studies that used controls with previous suspicion of prostatic cancer but a negative biopsy reported non-statistically significant difference in VEGF serum levels (pg/ml) between controls and localized prostate cancer patients (241 vs. 206; 69.5 vs. 55; 215.2 vs. 266.4). Higher VEGF plasma levels are observed in prostatic cancer patients compared with healthy controls, but serum levels do not appear to be useful in differentiating benign from malignant prostatic disease using, as controls, individuals with high risk of prostate cancer and negative biopsy. © 2010 Lippincott Williams & Wilkins, Inc.